EP2303844A1 - Styrylquinolines, leur procédé de préparation et leurs utilisations thérapeutiques - Google Patents

Styrylquinolines, leur procédé de préparation et leurs utilisations thérapeutiques

Info

Publication number
EP2303844A1
EP2303844A1 EP09780982A EP09780982A EP2303844A1 EP 2303844 A1 EP2303844 A1 EP 2303844A1 EP 09780982 A EP09780982 A EP 09780982A EP 09780982 A EP09780982 A EP 09780982A EP 2303844 A1 EP2303844 A1 EP 2303844A1
Authority
EP
European Patent Office
Prior art keywords
hydroxy
vinyl
quinolin
compound
anyone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09780982A
Other languages
German (de)
English (en)
Inventor
Bruno Giethlen
Mathieu Michaut
Claude Monneret
Emilienne Soma
Laurent Thibaut
Camille Georges Wermuth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioalliance Pharma SA
Original Assignee
Bioalliance Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08161000A external-priority patent/EP2147912A1/fr
Priority claimed from US12/269,241 external-priority patent/US20100120847A1/en
Application filed by Bioalliance Pharma SA filed Critical Bioalliance Pharma SA
Priority to EP09780982A priority Critical patent/EP2303844A1/fr
Publication of EP2303844A1 publication Critical patent/EP2303844A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • a subject of the present invention is quinoline derivatives, in particular endowed with inhibitory properties of Human Immuno-deficiency Virus (HIV) integrase. It also relates to a synthetic process for these derivatives and their biological uses.
  • HIV Human Immuno-deficiency Virus
  • the replication cycle of HIV and other retroviruses involves three major viral enzymes: reverse transcriptase, protease and integrase. Integrase catalyzes the integration of the viral DNA into chromosomal DNA of the host infected cell, it is an essential step for the replication of HIV and other retroviruses. Consequently, an integrase inhibitor constitutes ipso facto an accurate candidate for blocking infection by HIV, and possibly an effective therapeutic agent.
  • Polytherapy targeting reverse transcriptase and/or protease and/or integrase is today the only method to effectively combat the rapid development of the virus.
  • HIV reverse transcriptase and protease are each targeted by about 10 therapeutic agents.
  • integrase is targeted by only one commercialized medication: the Merck's lsentress (raltegravir or MK-0518), approved by the U.S. Food and Drug Administration (FDA) in October 2007.
  • FDA U.S. Food and Drug Administration
  • a second integrase inhibitor, Gilead's elvitegravir (GS-9137) is in advanced clinical trials.
  • the integration of the viral DNA into the chromosomal DNA of the infected cells occurs through a two-steps process: (i) in the "3' processing step", integrase in the cytoplasm of the host cell removes a dinucleotide from 3' end of the viral DNA, while (ii) in the "strand transfer step”, integrase in the nucleus catalyzes the insertion of the processed 3' end viral DNA into the host cell DNA.
  • Integrase inhibitors can be divided into two groups: (i) inhibitors of the 3' processing (referred to as INBIs) and (ii) selective strand transfer inhibitors (referred to as INSTIs) (Pommier Y, and al. Nat Rev Drug Discov 2005, 4:236- 248).
  • INBIs act as docking at the HIV DNA-binding site, preventing 3' processing and strand transfer and INSTIs act as occupying the infected cells DNA-binding site, thus only preventing strand transfer (Johnson AA et al. MoI Pharmacol. 2007 71 (3):893-901 ).
  • Raltegravir and elvitegravir belong to the INSTIs group.
  • WO 98/45269 discloses phenyl substituted quinolines, in particular styryl quinolines, where the various positions of the quinoleine and phenyl moieties may be optionally substituted.
  • the inventors have now showed that the presence of a substituent on the 5- position of the quinoline moiety, combined with a 8-OH on the quinoline core surprisingly leads to substantially increased properties, such as their antiviral efficacy, their stability, and/or their biodisponibility.
  • quinoline derivatives may present a low solubility
  • the inventors have designed suitable formulations of the compounds of the invention, allowing satisfying solubility.
  • the quinoline derivatives of the invention are moreover efficient against INSTIs resistant integrase.
  • the quinoline derivatives of the invention are particularly useful for inhibiting Raltegravir and/or Elvitegravir resistant integrase.
  • Another object of the invention is the combination of said quinoline derivatives with other anti viral agent(s). Indeed, said combinations, in particular those of quinoline derivatives with INSTIs or reverse transcriptase inhibitors, show synergistic effects.
  • the derivatives according to the invention are characterized in that they correspond to the general formula (I) :
  • - X represents a group chosen from a halogen atom, -OH, -OR, -COH, -COR, -COOH, -COOR, -NO 2 , CN; more preferably -COH, -COR, -OH or -NO 2 ; and/or
  • R4, R5, R6, R7, R8 are distinct of H;
  • R4, R5, R6, R7, R8 is OH; and/or - R6 is OH; and/or
  • Y is -COR;
  • the compounds of the invention are chosen from : - 1 - ⁇ 2-[2(E)-(3-chloro, 4,5-dihydroxyphenyl)-vinyl]-8-hydroxy-quinolin-5-yl ⁇ - ethanone;
  • Halo or halogen refers to fluorine, chlorine, bromine or iodine atom.
  • Alkyl represents an aliphatic-hydrocarbon group which may be straight or branched, having 1 to 20 carbon atoms in the chain unless specified otherwise. Preferred alkyl groups have 1 to 12 carbon atoms, more preferably have 1 to 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, 3-pentyl, octyl, nonyl, decyl.
  • Aryl refers to an aromatic monocyclic or multicyclic hydrocarbon ring system of 6 to 14 carbon atoms, preferably of 6 to 10 carbon atoms.
  • exemplary aryl groups include phenyl, naphthyl, indenyl, phenanthryl, biphenyl.
  • heterocycle or “heterocyclic” refer to a saturated or partially unsaturated non aromatic stable 3 to 14, preferably 5 to 10-membered mono, bi or multicyclic rings, wherein at least one member of the ring is a hetero atom.
  • heteroatoms include, but are not limited to, oxygen, nitrogen, sulfur, selenium, and phosphorus atoms.
  • Preferable heteroatoms are oxygen, nitrogen and sulfur.
  • Suitable heterocycles are also disclosed in the Handbook of Chemistry and Physics, 76th Edition, CRC Press, Inc., 1995-1996, pages 2-25 to 2-26, the disclosure of which is hereby incorporated by reference.
  • Preferred non aromatic heterocyclic include, but are not limited to oxetanyl, tetraydrofuranyl, dioxolanyl, tetrahydropyranyl, dioxanyl, pyrrolidinyl, piperidyl, morpholinyl, imidazolidinyl, pyranyl.
  • Preferred aromatic heterocyclic, herein called heteroaryl groups include, but are not limited to, pyridyl, pyridyl- ⁇ /-oxide, pyrimidinyl, pyrrolyl, imidazolinyl, pyrrolinyl, pyrazolinyl, furanyl, thienyl, imidazolyl, triazolyl, tetrazolyl, quinolyl, isoquinolyl, benzoimidazolyl, thiazolyl, pyrazolyl, and benzothiazolyl groups.
  • Alkyl also refers to the corresponding “alkylene”, “arylene”, “heterocyclene” which are formed by the removal of two hydrogen atoms.
  • the compounds herein described may have asymmetric centers.
  • substituted means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded and that the substitution results in a stable compound.
  • patient refers to a warm-blooded animal such as a mammal, preferably a human or a human child, which is afflicted with, or has the potential to be afflicted with one or more diseases and conditions described herein.
  • a "therapeutically effective amount” refers to an amount of a compound of the present invention which is effective in reducing, eliminating, treating or controlling the symptoms of the herein-described diseases and conditions.
  • controlling is intended to refer to all processes wherein there may be a slowing, interrupting, arresting, or stopping of the progression of the diseases and conditions described herein, but does not necessarily indicate a total elimination of all disease and condition symptoms, and is intended to include prophylactic treatment and chronic use.
  • pharmaceutically acceptable refers to those compounds, materials, compositions, or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, tartaric, citric, methanesulfonic, benzenesulfonic, glucoronic, glutamic, benzoic, salicylic, toluenesulfonic, oxalic, fumaric, maleic, and the like.
  • Further addition salts include ammonium salts such as tromethamine, meglumine, epolamine, etc., metal salts such as sodium, potassium, calcium, zinc or magnesium.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoechiomethc amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two.
  • non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418 and P. H. Stahl, CG. Wermuth, Handbook of Pharmaceutical salts - Properties, Selection and Use, Wiley-VCH, 2002, the disclosures of which are hereby incorporated by reference.
  • the invention also relates to a synthetic process for the derivatives defined above.
  • the compounds of formula (I) may be prepared in a number of ways well- known to those skilled in the art. In particular, they may be synthesized by application or adaptation of the process of preparation disclosed in WO 98/45269, or variations thereon as appreciated by the skilled artisan. The appropriate modifications and substitutions will be readily apparent and well-known or readily obtainable from the scientific literature to those skilled in the art.
  • the compounds of the present invention may contain one or more asymmetrically substituted carbon atoms, and may be isolated in optically active or racemic forms.
  • optically active or racemic forms all chiral, diastereomehc, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. It is well- known in the art how to prepare and isolate such optically active forms.
  • mixtures of stereoisomers may be separated by standard techniques including, but not limited to, resolution of racemic forms, normal, reverse-phase, and chiral chromatography, preferential salt formation, recrystallization, and the like, or by chiral synthesis either from chiral starting materials or by deliberate synthesis of target chiral centers.
  • bases include: sodium hydroxide, potassium carbonate, thethylamine, alkali metal hydrides, such as sodium hydride and potassium hydride; alkyllithium compounds, such as methyllithium and butyllithium; and alkali metal alkoxides, such as sodium methoxide and sodium ethoxide.
  • reaction are carried out in a suitable solvent.
  • solvents may be used, provided that it has no adverse effect on the reaction or on the reagents involved.
  • suitable solvents include: hydrocarbons, which may be aromatic, aliphatic or cycloaliphatic hydrocarbons, such as hexane, cyclohexane, benzene, toluene and xylene; amides, such as dimethyl-formamide; alcohols such as ethanol and methanol and ethers, such as diethyl ether and tetrahydrofuran.
  • the reactions can take place over a wide range of temperatures.
  • reaction it is convenient to carry out the reaction at a temperature of from OO to 150O (more preferably from about room temperature to 100O).
  • the time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to 20 hours will usually suffice.
  • the process of the invention is characterized in that it comprises the reaction of a quinaldine of formula (II) :
  • R2 ⁇ R4 ⁇ R5 ⁇ R6 ⁇ R7 ⁇ R8 ⁇ X' are defined as R1 , R2, R4, R5, R6, R7, R8, X above, provided any reactive function present in R1 , R2, R4, R5, R6, R7, R8, X may be protected by an appropriate protective group in R1 ', R2', R4', R5 ⁇ R6 ⁇ R7', R8 ⁇ X' respectively, and where Pg denotes either H or a protective group of the OH function if required, followed by the deprotection of any protective group present as appropriate.
  • the coupling may be advantageously conducted in an organic solvent, such as acetic anhydride and/or a mixture of pyhdine/water.
  • the reaction may be carried out at a temperature comprised between the room temperature and the boiling temperature of the reacting mixture.
  • OH groups may be protected in the form of acetoxy groups.
  • the deprotection may be conducted by hydrolysis.
  • the derivatives used as starting products in these syntheses are commercially available or easily accessible by synthesis for a person skilled in the art.
  • the derivatives of formula (II) may be synthesized in accordance with Meek et al., J. Chem. Engineering data, 1969, 14, 388-391 or Przystal et al, J.Heterocycl. Chem, 1967, 4, 131 -2.
  • the compounds of formula (III) are generally commercially available. If desired, the salts of the compounds of formula (I) may be obtained by adding the appropriate base or acid. For instance, where compounds of formula (I) comprise an acid function the sodium salt may be obtained by adding sodium hydroxide.
  • the process of the invention may also include the additional step of isolating the obtained product of formula (I).
  • the compound thus prepared may be recovered from the reaction mixture by conventional means.
  • the compounds may be recovered by distilling off the solvent from the reaction mixture or, if necessary after distilling off the solvent from the reaction mixture, pouring the residue into water followed by extraction with a water-immiscible organic solvent and distilling off the solvent from the extract.
  • the product can, if desired, be further purified by various well known techniques, such as recrystallization, reprecipitation or the various chromatography techniques, notably column chromatography or preparative thin layer chromatography.
  • the invention thus relates to pharmaceutical compositions characterized in that they contain an effective quantity of at least one derivative as defined above, in combination with pharmaceutically acceptable vehicles.
  • the present invention concerns formulations of a compound of formula (I) suitable for oral administration.
  • Said formulation may comprise one or more excipient(s) chosen from surfactant, emulsifier, solubility enhancers, etc...
  • the compounds of the invention are advantageously used in combination with other anti-viral agents, such as HIV medicaments, in particular medicaments endowed with an inhibitory effect vis-a-vis the integrase, reverse transcriptase and/or protease.
  • the compounds of the invention are active on resistant viruses, in particular viruses resistant to reverse transcriptase inhibitors and/or to INSTI integrase inhibitors.
  • the present invention thus also concerns such combinations of a compound of the invention with one or more integrase, reverse transcriptase and/or protease inhibitor(s), in particular, combinations of a compound of the invention with one or more INSTI inhibitor, such as raltegravir or elvitegravir.
  • the doses and administration methods are adapted as a function of the single-drug, two-drug or three-drug combination therapy treatment used.
  • the invention also relates to the use of the derivatives defined above as biological reagents usable in particular for mechanism studies concerning the viral infection.
  • the compounds of the invention may be advantageously used for inhibiting INSTIs resistant integrase.
  • a therapeutically effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques and by observing results obtained under analogous circumstances. In determining the therapeutically effective amount, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of subject; its size, age, and general health; the specific disease involved; the degree of involvement or the severity of the disease; the response of the individual subject; the particular compound administered; the mode of administration; the bioavailability characteristic of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
  • the amount of a compound of formula (I), which is required to achieve the desired biological effect will vary depending upon a number of factors, including the dosage of the drug to be administered, the chemical characteristics (e.g. hydrophobicity) of the compounds employed, the potency of the compounds, the type of disease, the diseased state of the patient, and the route of administration.
  • the compounds of this invention may be provided in an aqueous physiological buffer solution containing 0.1 to 10% w/v compound for parenteral and/or oral administration.
  • Typical dose ranges are from 1 ⁇ g/kg to 0.1 g/kg of body weight per day; a preferred dose range is from 0.01 mg/kg to 10 mg/kg of body weight per day.
  • a preferred daily dose for adult humans includes 1 , 5, 50, 100 and 200 mg, and an equivalent dose in a human child.
  • the preferred dosage of drug to be administered is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, and formulation of the compound excipient, and its route of administration.
  • unit dose means a single dose which is capable of being administered to a patient, and which can be readily handled and packaged, remaining as a physically and chemically stable unit dose comprising either the active compound itself, or as a pharmaceutically acceptable composition, as described hereinafter.
  • typical daily dose ranges are from 0.01 to 10 mg/kg of body weight.
  • unit doses for humans range from 0.1 mg to 1000 mg per day.
  • the unit dose range is from 1 to 500 mg administered one to four times a day, and even more preferably from 1 mg to 300 mg, once a day.
  • compositions can be formulated into pharmaceutical compositions by admixture with one or more pharmaceutically acceptable excipients.
  • Such compositions may be prepared for use in oral administration, particularly in the form of tablets or capsules; or parenteral administration, particularly in the form of liquid solutions, suspensions or emulsions; or intranasally, particularly in the form of powders, nasal drops, or aerosols; or dermally, for example, topically or via trans-dermal patches or ocular administration, or intravaginal or intra-utehne administration, particularly in the form of pessaries or by rectal administration.
  • compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art, for example, as described in Remington: The Science and Practice of Pharmacy, 20 th ed.; Gennaro, A. R., Ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2000.
  • Pharmaceutically compatible binding agents and/or adjuvant materials can be included as part of the composition.
  • Oral compositions will generally include an inert diluent carrier or an edible carrier.
  • the tablets, pills, powders, capsules, troches and the like can contain one or more of any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, or gum tragacanth; a diluent such as starch or lactose; a disintegrant such as starch and cellulose derivatives; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, or methyl salicylate.
  • a binder such as microcrystalline cellulose, or gum tragacanth
  • a diluent such as starch or lactose
  • a disintegrant such as starch and cellulose derivatives
  • a lubricant such as magnesium stearate
  • a glidant such as colloidal silicon dioxide
  • a sweetening agent such as sucrose or saccharin
  • a flavoring agent
  • Capsules can be in the form of a hard capsule or soft capsule, which are generally made from gelatin blends optionally blended with plasticizers, as well as a starch capsule.
  • dosage unit forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents.
  • Other oral dosage forms syrup or elixir may contain sweetening agents, preservatives, dyes, colorings, and flavorings.
  • the active compounds may be incorporated into fast dissolve, modified-release or sustained-release preparations and formulations, and wherein such sustained-release formulations are preferably bi-modal.
  • Preferred formulations include pharmaceutical compositions in which a compound of the present invention is formulated for oral or parenteral administration, or more preferably those in which a compound of the present invention is formulated as a tablet.
  • Preferred tablets contain lactose, cornstarch, magnesium silicate, croscarmellose sodium, povidone, magnesium stearate, or talc in any combination. It is also an aspect of the present disclosure that a compound of the present invention may be incorporated into a food product or a liquid.
  • Liquid preparations for administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • the liquid compositions may also include binders, buffers, preservatives, chelating agents, sweetening, flavoring and coloring agents, and the like.
  • Non-aqueous solvents include alcohols, propylene glycol, polyethylene glycol, acrylate copolymers, vegetable oils such as olive oil, and organic esters such as ethyl oleate.
  • Aqueous carriers include mixtures of alcohols and water, hydrogels, buffered media, and saline.
  • biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be useful excipients to control the release of the active compounds.
  • Intravenous vehicles can include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like.
  • Other potentially useful parenteral delivery systems for these active compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
  • formulations for inhalation which include such means as dry powder, aerosol, or drops. They may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally.
  • Formulations for buccal administration include, for example, lozenges or pastilles and may also include a flavored base, such as sucrose or acacia, and other excipients such as glycocholate.
  • Formulations suitable for rectal administration are preferably presented as unit-dose suppositories, with a solid based carrier, such as cocoa butter, and may include a salicylate.
  • Formulations for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil.
  • Carriers which can be used include petroleum jelly, lanolin, polyethylene glycols, alcohols, or their combinations.
  • Formulations suitable for transdermal administration can be presented as discrete patches and can be lipophilic emulsions or buffered, aqueous solutions, dissolved and/or dispersed in a polymer or an adhesive.
  • Alternative administrations include also solutions, ointments or other formulations acceptable for ocular administration.
  • the compound of the invention may be administered by the cutaneous, ocular or inhalation route as disclosed above.
  • formulations are particularly advantageous as they ensure a local treatment, without associated lymphopenia which may occur with systemic administration routes.
  • Figure 1 illustrates the cross-resistance assay results obtained with a compound of the invention on INSTIs mutants.
  • Figure 2 illustrates the cross-resistance assay results obtained with a compound of the invention on RTIs mutants.
  • the pET-15b-IN plasmid contains the cDNA encoding the HBX2 HIV integrase. His-tagged integrase protein was overexpressed in Escherichia coli BL21 (DE3) and purified under native conditions. Briefly, at an OD of 0.8, fusion protein expression was induced in bacterial cultures by the addition of IPTG (1 mM). Cultures were incubated for 3 h at 37O, af ter which cells were centhfuged.
  • the cell pellet was resuspended in ice-cold buffer A [20 mM Ths-HCI (pH 8), 1 M NaCI, 4 mM ⁇ -mercaptoethanol, and 5 mM imidazole], treated with lysozyme for 1 h on ice, and sonicated. After centhfugation (30 min at 10 000 rpm), the supernatant was filtered (0.45 ⁇ m) and incubated for at least 2 h with Ni- NTA agarose beads (Pharmacia). The beads were washed twice with 10 volumes of buffer A, 10 volumes of buffer A with 50 mM imidazole, and 10 volumes of buffer A with 100 mM imidazole.
  • His-tagged integrase was then eluted with buffer A supplemented with 50 ⁇ M ZnSO4 and 1 M imidazole. The integrase concentration was adjusted to 0.1 mg/mL in buffer A. The fusion protein was cleaved using thrombin and dialyzed overnight against 20 mM Ths-HCI (pH 8), 1 M NaCI, and 4 mM ⁇ -mercaptoethanol.
  • Oligonucleotides U5B ( ⁇ '-GTGTGGAAAATCTCTAGCAGT-S 1 ), U5B-2 (5 1 - GTGTGGAAAATCTCTAGCA-3'), U5A ( ⁇ '-ACTGCTAGAGATTTTCCACAC-S 1 ) were purchased from Eurogentec (Liege, Belgium) and further purified on an 18% denaturing acrylamide/urea gel.
  • strand transfer 100 pmol of U5B, U5B-2, respectively, were radiolabeled using T4 polynucleotide kinase and 50 ⁇ Ci of [ ⁇ -32P]ATP (3000 Ci/mmol).
  • T4 kinase was heat inactivated, and unincorporated nucleotides were removed using a Sephadex G-10 column (GE Healthcare). NaCI was added to a final concentration of 0.1 M, and complementary unlabeled strand U5A was added to either U5B or U5B-2. The mixture was heated to 90O fOr S min, and the DNA w as annealed by slow cooling.
  • strand transfer reactions were performed using U5A-U5B-2, in buffer containing 20 mM Tris (pH 7.2), 50 mM NaCI, 10 mM DTT, 1 OmM MgCI 2 .
  • the reaction was initiated by addition of substrate DNA (12.5 nM), IN 20OnM and the mixture was incubated for up to 2 h at 37O. Th e reaction was stopped by phenol/chloroform extraction, and DNA products were precipitated with ethanol.
  • the products were separated in TE containing 7 M urea and electrophoresed on an 18% denaturing acrylamide/urea gel. Gels were analyzed using a STORM Molecular Dynamics phosphorimager and quantified with Image QuantTM 4.1 software.
  • Hepes Buffer 0.5M, pH 7.5. 16 ⁇ l of drug at 25 mM, in 8 ml of Hepes Buffer. Different time points were done, Oh, 2h, 4h, 24h, and 48h.
  • the second stability assay consists in the assessment according to standard HPLC analysis protocols over 24 hrs in PEG400 and Vitamine E- TPGS/PEG 400 mixtures, by focusing on the evolution of the concentration and peak purity of the compound.
  • a mobile phase of water/acetic acid 0.1 % (Solvant A) : Acetonitrile/acetic acid 0.1 % (solvent B) mixture or a water/trifluoroacetic acid 0.1 % (Solvant A) : Acetonitrile/ trifluoroacetic acid 0.1 % (solvent B) mixture in the case of compound FZ41 was pumped according to a binary gradient described below, at a flow rate of 0.4 ml/min.
  • the compounds of the invention demonstrated high stability over 24 hrs at room temperature in several mixtures of excipients with less than 10% degradation, whereas FZ41 exhibited at least 10% degradation within only 3 hrs, as stated by the apparition of impurity peaks.
  • CEM cell were obtained from the American Type Tissue Collection (Rockville, MD).
  • a serial dilution of drugs is done to evaluate the cytotoxicity concentration and is identified by CC50 (concentration of drug which induces 50% of cytotoxicity)
  • the Hel_a-P4 was cultured in the presence or absence of compounds for 2 days. After this time period, cells were cultivated with MTT for 3 hours, further the medium is removed. And the lysis buffer is incubated for 1 hour, followed by plate reading at 540 nm in a microplate reader.
  • the antiviral activity is determined by infecting HelaP4 cells with a wild type HIV-1 virus (NL 4.3 strains at 3ng) on cells in presence or absence of drugs.
  • the effective concentration is the concentration of product at which virus replication is inhibited by 50 percent.
  • the quantification is done by the evaluation of ⁇ - Galactosidase produced by the infected HeIa P4 cells.
  • the viral activity is evaluated by colorimethc assay, CPRG, followed by plate reading at 570 nm with a reference of 690 nm.
  • the CPRG test is a colohmetric assay which allows to quantity the ⁇ -galactosidase produced by HIV-1 infected indicator cells (the ⁇ -Gal gene being under the control of the HIV-1 LTR).
  • the activity is determined by infecting CEM cells with a wild type HIV-1 virus (NL 4.3 strains at 3ng) on cells in presence or absence of drugs.
  • the effective concentration is the concentration of product at which virus replication is inhibited by 50 percent.
  • the quantification is done by the evaluation of the viral protein p24 with a commercial Elisa Kit.
  • P24 is a protein essential to the replication virus cycle. The quantification of this enzyme is proportional to the amount of virus produced by the infected cells.
  • Antiviral products targeting the same protein may develop mutations that lead to reduced susceptibility to one antiviral product and can result in decreased or loss of susceptibility to other antiviral products in the same drug class. This observation is referred to as cross- resistance. Cross-resistance is not necessarily reciprocal, so it is important to evaluate the activity of our new compounds on viruses containing mutations observed with other drugs of the anti-integrase class or reverse transcriptase inhibitors (RTI) class.
  • RKI reverse transcriptase inhibitors
  • Mutant viruses which are Raltegravir & Elvitegravir resistant were constructed on the NL43 backbone. Mutants viruses were as followed, where the first letter corresponds to the wild type amino acid, the number corresponds to the position of the amino acid in the integrase sequence and the second letter corresponds to the mutated amino acid. NL4.3 E92Q,
  • Resistant mutant viruses of RTI include K103N, Y178L, Y181 C, G190A, V108I/Q151 M, K103N/G190A, K103N/Y188C, K103N/Y181 C, M41 L/T215Y/K103N, M41 L/T215Y/Y181 C, M41 L/T215Y/M184V.
  • the assay to evaluate the activity against resistant viral strains is the same that antiviral assay. Instead of using a Wild-type virus, the virus studied contains mutations. The results are presented as a fold change corresponding to the ratio between the IC50 obtained for the mutant virus and the IC50 obtained for the wild type virus. More the virus is resistant to the compound more the fold change is elevated. If the mutation has no impact on the activity of the drug, the fold change is around 1.
  • a combination manifests therapeutic synergy if it is therapeutically superior to the addition of the therapeutic effects of the independent constituents.
  • the efficacy of a combination may be demonstrated by comparing the IC50 values of the combination with the IC50 values of each of the separate constituents in the study in question. This efficacy may be readily determined by the one skilled in the art.
  • a combination index (Cl) may be calculated, for instance using the computer program CalcuSyn software from Biosoft, for inhibition efficiencies of 50%, 75% or 90%.
  • the program CalcuSyn performs multiple drug dose-effect calculations using the Median Effect methods described by Chou et al Trends Pharmacol. Sci. 4:450-454, 1983 and Chou et al Enzyme Regul. 22, 27-55, 198', which are incorporated herein by reference.
  • the combination index (Cl) equation is based on the multiple dose effect equation of Chou et al derived from enzyme kinetics model.
  • the synergism is defined as a more than expected additive effect and antagonism as a less than expected additive effect.
  • (D1 ) and (D2) are the concentrations of drug 1 and 2, respectively, for which x % of inhibition is obeyed in the drug combination.
  • (Dx1 ) and (Dx2) are the concentrations of drug 1 and 2 respectively for which x % of inhibition is obeyed for drugs alone.
  • Synergistic interactions between compounds of the invention (SQE94) and INSTI (Raltegravir or RGV) were investigated using a NL43 HIV-1 laboratory strain replication assay. Virus infectivity in the presence of inhibitors was monitored with HelaCD4+ ⁇ -Gal indicator cells (P4 cells). Inhibition by combination of SQE94 and INSTI was evaluated at two fixed molar SQE94/ INSTI ratios: (i) 100:1 when the combination is tested on wild type virus and (ii) 6:1 when the combination is tested on INSTI resistant virus.
  • Step 1 preparation of HeLa P4 cells in a 96 flat bottom well plate
  • HeLa P4 cells per well are seeded in 100 ⁇ l of 10% FBS DMEM supplemented with 100UI/ml penicillin, 100 ⁇ g/ml streptomycin and 0.5 mg/ml geneticin (G418).
  • One plate is used for the 2 drugs alone.
  • Half a plate is used for the combination between the two drugs.
  • the cytotoxicity of the drugs alone and the combination is tested by MTT assay.
  • Step 2 Drug dilution
  • the dilutions tested for the "Wild type" virus are as follows: 16IC 5 o -> 8IC50 ⁇ 4IC 50 ⁇ 2IC 50 - ⁇ 1 IC 50 ⁇ * ICso/2 ⁇ IC 50 M-* IC 50 /8 ⁇ IC 50 /16 ⁇ IC 50 /32 Drugs alone :
  • the dilutions tested for the "INSTI's Mutants" virus are as follows: 60IC 50 -» 20IC 50 ⁇ 6,7IC 50 ⁇ 2,2IC 50 ⁇ 0,74IC 50 -» 0.25IC 50 ⁇ 0.08IC 50 ⁇ 0.03IC 50 ⁇ 0.009IC 50 ⁇ 0.003IC 50
  • Quinoline derivatives may present a low solubility in aqueous buffers at pH 5, 6 and 7. Two formulations were identified to solve this drawback:
  • Formulation A Tween 80/Labrafac® Lipophile/DMSO: 65/25/10
  • Formulation B Tween 80/Labrafil ® M1944 CS/DMSO: 65/25/10
  • Labrafil® and Labrafac® are solubility enhancers;
  • Labrafil® M1944 CS comprises Oleoyl Macrogolglycerides (Polyoxylglycehdes) and Labrafac® Lipophile is a mixture of Medium Chain Triglycerides.
  • LabrafacTM Lipophile WL 1349 and Labrafil M1944 CS are purchased from Gattefosse (France).
  • Solubility of compound SQE94 was determined in pH-buffers at pH values of 5, 6 and 7. 10 mg of SQE94 are added to 10 ml of each pH-buffer. Each solution is stirred at room temperature, away from light, for 24h, then centrifugated. The amount of dissolved compound is determined by HPLC analysis.
  • Solubility of compound SQE94 was determined in formulation A and B. 50 mg of product is dissolved in 5 mL of formulation and stirred at 37O for 24h, then centrifugated. The amount of dissolved compound is determined by HPLC analysis.
  • Formulated compound SQE94 (in formulation A or B) is diluted 1/10e with 37O pH-buffers (pH 5,6 and 7). Samples are immedia tely collected and centhfuged. The amount of dissolved compound is determined by HPLC analysis.
  • Formulation A and B enable to increase the solubility of compound SQE94 at pH 5, 6 and 7 by at least a 80-fold. These pHs mimic the pH within the intestinal tractus, where the maximum of absorption of a drug takes place. Results are summarized in following table : Dissolved Dompound SQE94 ( ⁇ g/ml)
  • Formulations A and B show good solubility, suitable to oral formulation of quinoline derivatives of the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouvelles styrylquinolines substituées, leur procédé de préparation et leurs utilisations thérapeutiques comme inhibiteurs de l'intégrase et/ou pour le traitement et/ou la prévention du VIH.
EP09780982A 2008-07-23 2009-07-23 Styrylquinolines, leur procédé de préparation et leurs utilisations thérapeutiques Withdrawn EP2303844A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09780982A EP2303844A1 (fr) 2008-07-23 2009-07-23 Styrylquinolines, leur procédé de préparation et leurs utilisations thérapeutiques

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08161000A EP2147912A1 (fr) 2008-07-23 2008-07-23 Styrylquinolines, leur procédé de préparation et leurs utilisations thérapeutiques
US12/269,241 US20100120847A1 (en) 2008-11-12 2008-11-12 Styrylquinolines, their process of preparation and their therapeutic uses
EP09305237 2009-03-13
EP09780982A EP2303844A1 (fr) 2008-07-23 2009-07-23 Styrylquinolines, leur procédé de préparation et leurs utilisations thérapeutiques
PCT/EP2009/059494 WO2010010149A1 (fr) 2008-07-23 2009-07-23 Styrylquinolines, leur procédé de préparation et leurs utilisations thérapeutiques

Publications (1)

Publication Number Publication Date
EP2303844A1 true EP2303844A1 (fr) 2011-04-06

Family

ID=41131767

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09780982A Withdrawn EP2303844A1 (fr) 2008-07-23 2009-07-23 Styrylquinolines, leur procédé de préparation et leurs utilisations thérapeutiques

Country Status (2)

Country Link
EP (1) EP2303844A1 (fr)
WO (1) WO2010010149A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2125750B1 (fr) 2007-02-26 2014-05-21 Vitae Pharmaceuticals, Inc. Inhibiteurs d'urée et de carbamate de 11beta-hydroxystéroïde déshydrogénase 1 cycliques
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
JP5490014B2 (ja) 2007-12-11 2014-05-14 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の環状尿素阻害剤
CA2722427A1 (fr) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Inhibiteurs cycliques de la 11-beta-hydroxysteroide dehydrogenase 1
RU2539979C2 (ru) 2008-07-25 2015-01-27 Вайтаи Фармасьютиклз, Инк. Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
JP5777030B2 (ja) 2008-07-25 2015-09-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤
WO2010089303A1 (fr) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh Inhibiteurs cycliques de la 11β-hydroxystéroïde déshydrogénase de type 1
MA33216B1 (fr) 2009-04-30 2012-04-02 Boehringer Ingelheim Int Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
EP2440537A1 (fr) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Inhibiteurs cycliques de la 11-bêta-hydroxystéroïde déshydrogénase 1 basée sur la structure 1,3-oxazinan-2-one
WO2011002910A1 (fr) 2009-07-01 2011-01-06 Vitae Pharmaceuticals, Inc. Inhibiteurs cycliques de la 11-bêta-hydroxystéroïde déshydrogénase 1
EP2582698B1 (fr) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Hétérocycles à 5, 6 et 7 chaînons substitués, médicaments contenant ces composés et leur utilisation
JP5813106B2 (ja) 2010-06-25 2015-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン
BR112013010021A2 (pt) 2010-11-02 2019-09-24 Boehringer Ingelheim Int combinações farmacêuticas para o tratamento de distúrbios metabólicos.
CN102924374B (zh) * 2012-02-15 2014-04-16 湖北欣瑞康医药科技有限公司 喹啉-4-羧酸衍生物的制备方法
US10041408B2 (en) * 2015-02-13 2018-08-07 United Technologies Corporation Turbine engine with a turbo-compressor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1902595A1 (de) * 1969-01-20 1970-08-13 Soc D Etudes Prod Chimique Neue Chinolin-Derivate und Verfahren zu ihrer Herstellung
WO2006129134A1 (fr) * 2005-06-01 2006-12-07 Bioalliance Pharma Combinaisons synergiques comprenant un compose de styrylquinoleine et d'autres agents therapeutiques contre une infection au vih

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010010149A1 *

Also Published As

Publication number Publication date
WO2010010149A1 (fr) 2010-01-28

Similar Documents

Publication Publication Date Title
US20110224242A1 (en) Styrlyquinolines, their process of preparation and their therapeutic uses
WO2010010149A1 (fr) Styrylquinolines, leur procédé de préparation et leurs utilisations thérapeutiques
JP4405602B2 (ja) ヒストン脱アセチル化酵素阻害剤
US6670377B1 (en) Quinoline derivatives, having in particular antiviral properties, preparation and biological applications thereof
TWI580668B (zh) Ｂ型肝炎抗病毒劑
US20210017153A1 (en) Ahr inhibitors and uses thereof
TW200831085A (en) Non-nucleoside reverse transcriptase inhibitors
CA2658479A1 (fr) Inhibiteurs inedits de la transcriptase inverse du vih
US20140094485A1 (en) Solid state forms of hiv inhibitor
CN111662281B (zh) 水杨酸类小檗碱型生物碱季铵盐及其制备药物的用途
CN103842350B (zh) 作为dhodh抑制剂的五元二氢杂环酮类衍生物及应用
US9447103B2 (en) Inauhzin analogues that induce P53, inhibit cell growth, and have antitumor activity
CA2984974A1 (fr) Derives d'indenoindole, sels pharmaceutiquement acceptables ou isomeres optiques de ceux-ci, leur procede de preparation et compositions pharmaceutiques les contenant en tant que principe actif pour la prevention ou le traitement de maladies virales
WO2015000431A1 (fr) Carbamate de tizoxanide et son utilisation pharmaceutique
JP6373297B2 (ja) １，３−ジオキソインデン誘導体、その薬学的に許容される塩又は光学異性体、その調製方法及びそれを抗ウイルス活性成分として含有する医薬組成物
JP7625527B2 (ja) 置換された３，４，１２，１２ａ－テトラヒドロ－１Ｈ－［１，４］オキサジノ［３，４－ｃ］ピリド［２，１－ｆ］［１，２，４］トリアジン－６，８－ジオン、その医薬組成物、生産のための方法および使用
WO2010010148A1 (fr) Styrylquinolines, leur procédé de préparation et leurs utilisations thérapeutiques
CN110013483B (zh) 噻唑并[3,2-a]嘧啶-6-甲腈衍生物用于抗菌的用途
WO2010010147A1 (fr) Styrylquinolines, leur procédé de préparation et leurs utilisations thérapeutiques
WO2014012467A1 (fr) Composé diarylaniline ou diarylpyridinamine et son procédé de préparation et son utilisation médicale
US20100120847A1 (en) Styrylquinolines, their process of preparation and their therapeutic uses
US7863323B1 (en) Flavonols
CN110407765A (zh) 1,2,5-噁二唑类衍生物、其制备方法及其在医药上的应用
JPS6232170B2 (fr)
EP2147912A1 (fr) Styrylquinolines, leur procédé de préparation et leurs utilisations thérapeutiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110121

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130201